Form 4: Dynavax Technologies COO David Novack Sells Shares Under 10b5-1 Trading Plan

Dynavax Technologies' President and COO, David Novack, sold 14,020 shares of common stock on March 18, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 18, 2025, David Novack, the President and COO of Dynavax Technologies Corp, sold 14,020 shares of the company's common stock.
• The sales were executed under a 10b5-1 trading plan adopted on December 6, 2024.
• The transactions occurred at prices ranging from $13.47 to $13.66, with a weighted average sale price of $13.58.
• Following the reported transaction, Novack directly owns 8,078 shares of Dynavax common stock.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is neither positive nor negative without additional context about the company's performance or the reasons behind the sale.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through 10b5-1 trading plans to avoid accusations of insider trading. The market typically analyzes these sales in the context of the company's overall performance and future prospects.

Stakeholder Impact

• Shareholders may react to the insider sale, depending on the size and context of the transaction.
• The sale could be perceived negatively if it suggests a lack of confidence by the COO, or positively if it's seen as routine diversification.

Key Dates

Keywords

Dynavax Technologies, David Novack, Form 4, Share Sale, 10b5-1 Trading Plan, DVAX, Insider Trading